Vaxcyte was founded by Grant Pickering, Grant E. Pickering.

Who are Vaxcyte's investors?

Vaxcyte's investors include BioRock Ventures, CTI Life Sciences Fund L.P., Foresite Capital, Frazier Life Sciences, Longitude Capital, Pivotal Life Sciences, RA Capital, Dolby Family Ventures and 2 more.

Vaxcyte

NASDAQ: PCVX

10 known investors

Find your way into Vaxcyte

515 people in our graph share verified history with the Vaxcyte team — schools, employers, funds. One of them is your warm intro.

Eavan Murrayunlockedknows Grant Pickering · together at Vaxcyte (overlapped)

×5knows the team · via Vaxcyte

×6knows the team · via Kleiner Perkins

Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections, using a cell-free protein synthesis platform and synthetic chemistry techniques. Its pipeline includes pneumococcal conjugate vaccines (VAX-31 and VAX-24) and early-stage candidates targeting Group A Strep and Shigella.

Biotech Healthtech

Founders & leadership

Grant Pickering Co-Founder, CEO, DirectorFounder of Vaxcyte, which develops vaccines to prevent bacterial infections using a cell-free protein synthesis platform. He has held leadership roles in the development and commercialization of several life science products, including Provenge, Flonase, Victrio, and Zelnate, with experience in biopharmaceutical commercialization, clinical development, fundraising, and corporate development.

Grant E. Pickering Co-Founder, CEO, DirectorGrant E. Pickering is Chief Executive Officer of Vaxcyte, a company developing vaccines against bacterial infections. He previously led development and commercialization efforts for multiple biopharmaceutical products including Provenge, Flonase, Victrio, and Zelnate.

Investors · 10

BioRock Ventureslisted by BioRock VenturesSan Franciscovia Mary Wheeler · inferred

How we know: BioRock Ventures's portfolio page · Not right? Tell us

CTI Life Sciences Fund L.P.listed by CTI Life Sciences Fund L.P.Montréal

Foresite Capitallisted by Foresite CapitalWest Hollywood

How we know: Foresite Capital's portfolio page · Not right? Tell us

Frazier Life Scienceslisted by Frazier Life SciencesPalo Alto

How we know: Frazier Life Sciences's portfolio page · the S-1 prospectus · Not right? Tell us

Longitude Capitallisted by Longitude CapitalMenlo Park · $10M – $30M

How we know: Longitude Capital's portfolio page · the VCSheet dataset · Not right? Tell us

Pivotal Life Scienceslisted by Pivotal Life SciencesSan Francisco

How we know: Pivotal Life Sciences's portfolio page · the S-1 prospectus · Not right? Tell us

RA Capitallisted by RA CapitalBoston

How we know: RA Capital's portfolio page · the S-1 prospectus · Not right? Tell us

Dolby Family VenturesreportedSan Francisco

How we know: a partner's Signal profile · Not right? Tell us

Janus Henderson InvestorsreportedLondon

How we know: the S-1 prospectus · Not right? Tell us

MedicxireportedLondon

How we know: the S-1 prospectus · Not right? Tell us

Valuation · disclosed

Disclosed events

$774.2Mvaluation at IPOJun 2020 · $16.00/share · 424B4

filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Competitors · 2

by search overlap

Dynavax NASDAQ: DVAX www.dynavax.com43 shared keywordsDynavax is a commercial-stage biopharmaceutical company that develops and commercializes vaccines against infectious diseases using its adjuvant technology. Its products target immunization and infectious disease prevention.

Vaccinex40 shared keywordsVaccinex is a clinical-stage biotechnology company developing pepinemab (VX15/2503), a humanized monoclonal antibody that blocks SEMA4D signaling, in trials for neurological disorders such as Huntington's and Alzheimer's disease and for solid tumors including breast cancer, melanoma, non-small cell lung cancer and head and neck cancer. It also offers a fusion protein and ActivMab antibody discovery technology for incorporating membrane proteins such as GPCRs and ion channels into poxviruses for antibody selection.

Companies competing with Vaxcyte for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Vaxcyte do?: Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections, using a cell-free protein synthesis platform and synthetic chemistry techniques. Its pipeline includes pneumococcal conjugate vaccines (VAX-31 and VAX-24) and early-stage candidates targeting Group A Strep and Shigella.
Who founded Vaxcyte?: Vaxcyte was founded by Grant Pickering, Grant E. Pickering.
Who are Vaxcyte's investors?: Vaxcyte's investors include BioRock Ventures, CTI Life Sciences Fund L.P., Foresite Capital, Frazier Life Sciences, Longitude Capital, Pivotal Life Sciences, RA Capital, Dolby Family Ventures and 2 more.